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ABSTRACT 
Observational study designs are often used in medical research. Swedish national registers 
have successfully been used as data sources for such observational studies in other 
rheumatic diseases. The Swedish health care system is tax funded and does together with 
the ability to link multiple national registers, allowing for longitudinal follow-up, make up a 
great setting for answering many research questions in a real world setting. 
We identified 95 patients with idiopathic inflammatory myopathies (IIM) treated with 
different biologic therapies between 2000 and 2011 in study 1. All had previously been 
treated with prednisolone and at least one Disease modifying anti-rheumatic drug 
(DMARD). Rituximab was the most commonly used drug and even though large variations 
were seen in treatment length, no conclusions could be made regarding effectiveness. 
Between 2007 and 2011 we found an average incidence rate of 11 per 1 000 000 person-
years for IIM in Sweden in study 2. We observed a general increase in incidence with age 
and a peak was observed in the 50-79 year age groups and the highest incidence rate was in 
the 70-79 year age group. No difference in incidence was observed for different levels of 
education or population density and even though large variations were seen between 
Sweden´s 21 counties, no north to south gradient was observed. 
In study 3 we conducted a case-control study with IIM as the outcome and respiratory 
diseases and infections as the exposure. Previous infections were associated with increased 
future risk to develop IIM, OR 1.5. The risk was elevated for both infections of the 
respiratory tract and gastrointestinal tract but not for infections of the skin. Respiratory 
diseases were less common than infections but the relative risk was higher, odds ratio (OR) 
2.3, and was elevated for both upper and lower respiratory tract diseases. A dose-response 
relationship between number of visits indicating exposure increased the risk of IIM for both 
respiratory diseases and infections. 
In Study 4 we used a cohort study design to address if the risk of stroke is increased 
following IIM diagnosis. We identified 663 newly diagnosed IIM patients and 6673 general 
population comparators without prior stroke or stroke-related events. 
We found an increased risk of both ischemic and haemorrhagic stroke (HS), hazard ratio 
(HR) 1.7 and 2.3 respectively. Because the number of HS were rare we did not further 
analyse this outcome. For IS, the rate differences were the highest in the oldest age group 
(≥68) and in men relative risk of IS was highest in the youngest age group (<56 years).  
When accounting for the competing risk of death, the HR for IS was decreased by 40% and 
the cumulative incidence was increased in IIM patients compared to the general population 
directly following diagnosis but they were similar after 10 years. 
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1.1 WHAT IS EPIDEMIOLOGY? 
Epidemiology is a research field with the goal to better understand disease and health 
conditions, their occurrence, causes and consequences. Common questions include:  
- How common is a disease?  
o How many get the disease over a time period (incidence)? 
o How many have the disease at a specific time (prevalence)? 
- What is the chance of experiencing a certain event after contracting a specific disease? 
- Does a specific factor increase the risk of disease?  
Most commonly, epidemiologists seek to investigate the effect of an exposure on an 
outcome. An example can be smoking´s effect (the exposure) on lung cancer risk (the 
outcome). 
The most obvious way to investigate the effects of an exposure is via an experiment, like a 
clinical trial. You give one group of individuals packets of cigarettes and tell them to start 
smoking, while the other group is not allowed to smoke. Of course this type of study will never 
be conducted, because it is unethical, but we can imagine it could be possible. If you also 
randomize individual allocation of the groups (smoker/non-smoker) the average difference in 
outcome (lung cancer) between the two groups, is the average causal effect of the 
intervention. This type of experiment is called a randomized clinical trial (RCT) and has long 
been deemed the gold standard when trying to establish the causal effect of an intervention. 
The problem is that RCTs are not feasible in many situations, are difficult to make inferences 
from due to a highly selected study populations, might be unethical and finally, are extremely 
expensive. That is why observational data are used to answer many questions in medical 
research. Observational data are often collected in a less controlled setting than in RCTs and 
because individuals are not randomized to a specific intervention, the groups may differ in 
other factors. Such factors, like age, can affect both the exposure and outcome and therefore 
cause an association that is not casual. Factors causing such associations are what 
epidemiologists call confounders and such factors are often the core issue with observational 
data. Other sources of bias, or systematic errors, include how people have been selected into 
the population and the analyses and many of the methods used by epidemiologists are 
performed to reduce and remove these sources of bias. Of course there are other problems 
with observational data. Often, at least in the setting of this thesis, the data are not collected 
for the purpose of research and therefore there might be problems with data quality and 
missing information. Sweden has some incredible data sources for this type of research and 
is a great setting for conducting observational studies. We have a strong history of collecting 
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data in a structured way in national registers covering the whole population. Information on 
when you go to the hospital or when you pick up a prescription at the pharmacy, where you 
live and what level of education you might have is all listed in different registers. The personal 
identity number (PIN) (1) enables linking between different register source and makes it 
possible to follow individuals through time. 
In this thesis I have used epidemiological methodology to answer questions on one specific 
disease, Idiopathic inflammatory myopathies (IIM), collectively called myositis. We have 
estimated disease occurrence, described treatments, investigated risk factors and looked at 
prognosis and risk of co-morbid conditions of this disease. In the first two studies, the disease 
and treatments were described while in the third and fourth study we have answered causal 
and prognostic questions. 
1.2 IDIOPATHIC INFLAMMATORY MYOPATHIES 
1.2.1 Clinical description 
Idiopathic inflammatory myopathy (IIM) is a rare rheumatic disease mainly affecting skeletal 
muscle but other organs such as the lung and cardiac system are often involved suggesting it 
is a systemic inflammatory disease. Patients with IIM present a wide variety in symptoms and 
is commonly divided into three clinical sub diagnoses based on clinical, pathological, histology 
and laboratory findings. Some findings are shared, like muscle weakness and inflammatory 
infiltrates in skeletal muscle, while presence or absence of other help in the diagnostic work 
up and subgrouping of patients with IIM. Primarily proximal muscles are involved in 
polymyositis (PM) and dermatomyositis (DM) and respiratory muscles may also be involved 
in advanced cases (2). Inclusion body myositis (IBM) was acknowledged as a standalone entity 
in 1978 (3) while diagnostic criteria was introduced as late as 1995 (4). The most commonly 
used criteria for PM and DM was introduced in 1975 and were suggested both as diagnostic 
and classification criteria. (5,6). IBM is characterized by both proximal and distal muscle 
weakness, slower disease progression, over months and years, and generally poorer response 
to treatment compared to PM and DM (7). Muscle weakness normally progress over weeks 
to month for PM and DM and commonly affected muscles include neck-flexors, hip-girdle and 
shoulder muscles. For DM patients, the skin is also involved in form of characteristic rashes 
including heliotrope rash (affecting the eyelids) and Gottron papules (affecting knuckles and 
elbows). DM affects adults as well as children and is then called juvenile DM (JDM). For IBM 
quadriceps, finger flexors and pharyngeal muscles are typically involved affecting the ability 
to stand up from a chair, grip strength and ability to swallow. Other newer clinical sub 
diagnoses include immune mediated necrotizing myopathies and overlap myositis but they 
will not be discussed specifically in this thesis (8). 
The cause of IIM is largely unknown but inflammatory infiltrates in muscle tissue of IIM 
patients are dominated by T-cells and macrophages, This feature of muscle tissue and the 
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presence of both myositis specific antibodies (MSA) and myositis associated antibodies 
(MAA), antibodies that can be present in other autoimmune diseases like systemic lupus 
erythematosus and systemic sclerosis (9), suggest that an autoimmune component is involved 
in the development of IIM (10). In addition, muscle degenerative features of disease may also 
play a role, in particular for IBM (11). 
The diagnosis of IIM may be difficult to establish, it requires extensive investigation and 
misclassification is not uncommon. Advances in muscle histopathology, use of magnetic 
resonance imaging (MRI) and identification of MSA have made diagnosis easier. The 
classification criteria for PM and DM was for instance updated to include antibody and MRI 
findings in 1997 (12).  
1.2.2 Treatment 
1.2.2.1 Traditional pharmacological treatment 
Traditionally IIM is treated with high doses of glucocorticoids, such as prednisolone, as first 
line treatment. The introduction of glucocorticoids has improved the care and prognosis for 
this patient group but many individuals experience side effects and have limited response to 
treatment (13). Disease modifying anti-rheumatic drugs (DMARDs), such as methotrexate or 
azathioprine, are recommended for use in combination with prednisolone to decrease 
prednisolone side effects and to improve treatment outcome (10,13–17). Other DMARDs, 
such as cyclosporine as well as high-dose intravenous gammaglobulins (IVIG) are often used 
as second line therapies (10). Randomized control trials are largely lacking in patients with IIM 
thus treatment recommendation are mainly based on open studies and case reports. Using 
currently available therapies still many patients with IIM fail to regain their former muscle 
strength and there is a strong unmet need for new therapies (7,18). 
1.2.2.2 Biologic therapies 
The need for new therapeutical options is obvious for all sub groups of IIM and biological 
agents have, since their introduction in the beginning of the millennia, had a large impact on 
how other autoimmune diseases like rheumatoid arthritis (RA) are being treated. Biologics 
agents are, in contrast to tradition small molecular drugs, proteins which generally target 
specific signal molecules or cells and are therefore said to have a more precise effect 
compared to traditional pharmacological treatment. These biologic agents have been used to 
treat IIM but in an off-label setting, meaning they are not formally approved for treatment of 
IIM and in 2011, many different biologics in addition to mycophenolate mofetil, tacrolimus, 
cyclophosphamide were included in guidelines as third line therapies (10).  
Multiple case reports, case series and few prospective clinical trials have reported on use and 
effectiveness of biologics in IIM, often with varying results. Early case reports presented 
positive treatment responses for TNF-inhibitors (19–21) while later reports were more 
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contradicting. TNF-inhibitors have both been associated with increased number of flares (22) 
and found to have a favourable response in some patients (23,24). The same is true for 
anakinra which has shown a favourable response in one study on overall IIM (25) while no 
effect was seen in a small pilot study of IBM patients (26). Rituximab has been reported to be 
effective in small pilot studies (27,28) and case reports (29–31) while the largest trial to date, 
a randomize placebo controlled trial, the Rituximab in Myositis (RIM)-study, including 200 
patients, failed to reach the primary end-point, time to improvement (32). Still, 83 % of 
rituximab-treated patients with refractory adult and juvenile DM and PM met the definition 
of improvement at the end of the 44-week trial RIM study and a post hoc analysis of the 
results found that anti-Jo1-antibodies, the most common MSA, was associated with a 
favourable response (33). Abatacept has been reported as effective in three case reports (34–
36) but had not been investigated in any larger trial when planning this thesis. In summary, 
the use and safety of biologic drugs still remain unknown and further studies are needed to 
investigate how they are used in IIM. 
1.2.3 Epidemiology/Occurrence 
In Sweden, incidence of PM and DM has previously been estimated to 7.6 per 1 000 000 
person-years between 1984 and 1993 in one county, Gävleborg (37) while incidence for IBM 
has been estimated to 2.2 per 1 000 000 person-years in Gothenburg between 1983 and 1992 
(38). Internationally, the occurrence of IIM has been estimated in many previous studies but 
with large variation of estimates (Figure 1). The available estimates of incidence rates for IIM 
range between 1.2 and 66 per 1 000 000 person-years (37,39–48). The prevalence of IIM has 
also varied greatly in previous studies, between 2.9 to 3.4 per 100 000 (40,43,47–52). Register 
based studies from the U.S. and Canada have estimated the highest prevalence of IIM, 
between 17 and 34 per 100,000 (40,47,53).   
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Figure 1. Previously estimated incidence rates of idiopathic inflammatory myopathies. 
It is reasonable to believe that the estimates would vary to some degree between different 
populations due to different genetic and environmental factors but much of these large 
differences can probably be explained by differences in methodology. The definition of IIM, 
increased awareness and the introduction of new diagnostic criteria all affect estimates. Some 
studies are based on investigations of single hospitals or local regions using retrospective 
chart reviews and diagnostic criteria to ascertain IIM diagnosis. The specificity when using 
medical charts to ascertain diagnosis is often high but there is a high risk of missing cases due 
to the stringency of most criteria and the difficulty of collecting information on these criteria 
retrospectively. Also, estimates from small geographical regions are uncertain, particularly for 
rare disorders, because of the small source population generating cases. All of the above 
factors make comparisons between studies difficult and the true occurrence of IIM is still 
uncertain.  
1.2.4 Risk factors 
Not much is known about the aetiology of IIM but as with many other autoimmune diseases 
it is believed to be caused by an interaction of environmental and genetic risk factors. For IIM, 
both infectious and non-infectious agents have been suggested as potential environmental 
risk factors but most studies available on IIM risk factors are based on case studies or series, 
historical cohorts or have used a cross sectional design (54) making it difficult to say anything 
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about the temporality of the association. Still, evidence of temporal clustering 
(39,40,42,43,48) found in various regions of the world (USA, Israel, Australia and Japan) and 
spatial clustering (49,55) could support the hypothesis of involvement of environmental 
factors and specific factors have been suggested including UV-light (56,57). Additionally, some 
studies have found seasonal variation in incidence of IIM (58,59) which would further support 
this hypothesis. On the other hand, others have failed to find evidence of such variations (55).  
1.2.4.1 Respiratory risk factors 
The lung is the most commonly involved extramuscular organ in IIM and up to 65% of patients 
have been reported to show signs of interstitial lung disease (ILD) at time of diagnosis (60,61) 
and 78% of prevalent patients (62). Respiratory exposures have previously been suggested to 
be triggers of disease or that the immunological events that eventually will target muscles 
actually start in the lung. No clear evidence for this causal path have been presented but the 
finding of an interaction between smoking and the allele HLA-DRB1*03 could predict anti-Jo-
1 antibody production could support this hypothesis (63). A strong reason for us to include 
respiratory risk factors in the third study was preliminary data from a retrospective case 
control study carried out at Karolinska using questionnaires which found that history of 
pulmonary disease was present in IIM to a higher degree compared to controls (64) but the 
role of pulmonary inflammatory conditions like infections, ILD, asthma and chronic 
obstructive pulmonary disease (COPD) in the development of IIM has not been well 
investigated 
In rheumatoid arthritis, smoking is an established risk factor for developing disease and there 
is a strong gene environment interaction between certain HLA-DR4 genotype and smoking 
(65,66). Also other airway exposures including silica dust (67) traffic pollution (68) and textile 
dust (69) and it is hypothesized that inflammatory events in the lungs may play a role in the 
immune activation leading to anti-citrullinated protein antibodies that later may lead to 
rheumatoid arthritis.  
1.2.4.2 Infectious risk factors 
Many types of infections have previously been reported to be associated with IIM and 
suggested as potential triggers of disease. Both viral, including Epstein Barr virus, hepatitis, 
retroviruses, enteroviruses (70–74) and  bacterial infections such as streptococcus, 
tuberculosis and borrelia (54,75) have been suggested while one study have presented 
negative results on enterovirus (76). Reports of infectious risk factors in IIM is primarily 
presented from case reports or case studies or have been assessed at or after disease 
diagnosis through questionnaires or antibody tests making results uncertain and population 
based studies are lacking. 
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Autoimmune disease can follow infection by multiple different mechanisms. Either through 
the effect of drugs used to treat infections like antibiotics and antiviral medication, change in 
the gut microbiome, molecular mimicry or a general activation of the immune system (77,78). 
In other autoimmune diseases, the same link with infections have been suggested but a 
recent study on RA reported that a history of gut infection decreased the risk to develop RA 
(79). Thus the role of infections in autoimmune diseases has not been clarified. 
1.2.5 Co-morbidities and prognosis 
The care of IIM has certainly improved over time but the disease is still associated with 
significant increased mortality and morbidity mainly due to cardiovascular disease, 
pulmonary disease and cancer (80). Quality of life is often affected because of impaired 
muscle function and up to 80% of patients have a chronic or cyclic disease with frequent 
repeating flares (81). Reported survival has varied but improved over time (80,82–84). 
1.2.5.1 Cardiovascular manifestations 
The most common heart manifestations in IIM are conduction abnormalities and arrhythmias. 
These manifestations are normally sub-clinical and might not have been given much attention 
in IIM care. An increased risk for more serious CVD, like VTE (85,86), have, however, been 
shown in some studies but much is still unknown about the risk for other serious CVD like 
unstable angina, ischemic stroke and myocardial infarction.  
1.2.5.2 Stroke 
Stroke is the third most common cause of death in Sweden and approximately 20 000 strokes 
occur yearly in Sweden (87) . Stroke is defined as an event inhibiting the blood flow to a part 
of the brain either via blockage (ischemic stroke) or the rupture of a blood vessel 
(haemorrhagic stroke). Stroke is a complicated event to treat acutely because of them being 
the complete opposite of each other regarding treatment. Stroke often has catastrophic 
consequences and besides death, often leads to damage of parts of the brain with 
neurological deficits in survivors with large impact on daily life.  
An increased risk have been shown in other inflammatory disease like SLE and RA (88–90) and 
a few previous cohort studies have identified an increased risk of stroke in PM and DM 
patients with relative risk ranging between 1.67 and 3.46 (91–93). However, failure to 
separate IS from HS and differences in study population selection (hospitalized cases), follow-
up and comparison groups still make the risk in IIM uncertain and none has taken the 
competing risk of death into account. 
1.2.5.3 Cancer 
Case reports first started reporting about the association between PM and DM with solid 
tumours and it has since then been established in epidemiologic studies and is associated with 
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worse prognosis (80). Risk of cancer is increased both before and after diagnosis in one meta-
analysis (94) while another reported DM being associated with a wide range of cancers while 
PM only was associated with a few types of cancers (95). 
2 OBJECTIVES / AIMS 
The overall aim of this thesis was to further the understanding of the rheumatic muscle 
disease IIM by using observational study designs and multiple Swedish register sources. 
The specific aims include: 
1. To describe the use of biologic agents in treatment of IIM in Sweden by identifying all 
patients treated with biologics in Sweden (study 1). 
2. To develop a robust register based algorithm to identify IIM and to estimate the 
occurrence of disease, how it varies with age, gender, region and level of education 
(study 2). 
3. To investigate if infections and respiratory diseases affect the risk of developing IIM 
(study 3). 
4. To assess the risk of stroke in patients with IIM, to identify specific risk groups and 
describe how risk varies during disease course (study 4). 
 
3 MATERIALS AND METHODS 
3.1 SETTING 
The Swedish health care system is tax funded and provides public health care and prescription 
drugs succeeding a threshold of 1100 SEK and 2200 SEK per year respectively since 2012 (900 
SEK and 1800 SEK prior 2012). In Sweden, patients with IIM are typically seen by specialist in 
rheumatology or neurology or in some regions/hospitals, specialist in internal medicine or 
dermatology are responsible for their care. Individuals under 18 years of age are treated at 
paediatric clinics. The reporting to administrative register sources are mandatory in a 
specialist outpatient and inpatient setting which results in almost complete coverage of such 
health care contacts for all Swedish residents.   
The personal identity number (PIN) consists of 10 digits allocated to all Swedish residents 
since 1947 and administered by the Swedish tax agency (1). The PIN is used to identify 
patients in different register sources and enables individual information from different 
register sources and the possibility to combine such individual information. 
3.2 DATA SOURCES 
Here different register sources used in this thesis are described. 
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3.2.1 National health registers 
3.2.1.1 The Swedish National Patient Register 
The most important source used in this thesis is the national patient register (NPR) used to 
identify the majority of diseases, exposures, outcomes and other variables. 
The NPR covers nationwide information on hospitalizations since 1964, nationwide since 
1987, and outpatient visits in non-primary care since 2001. The coverage is 100% for inpatient 
care and somewhat lower for outpatient care mainly due to lower reporting from private and 
psychiatric care (96). Information on primary and contributory diagnoses and procedures are 
coded according to International Classification of Disease (ICD) versions 7 through 10 for each 
visit, and version 10 (ICD10) has been used since 1997. 
3.2.1.2 The Prescribed Drug Register  
The Prescribed Drug Register (PDR) lists information on all dispensed prescriptions from 
Swedish Pharmacies since July 2005 while no information on drugs given in ambulatory care 
is registered. Information on drugs is stored using Anatomical Therapeutic Chemical (ATC) 
code, amount and route of administration. 
3.2.1.3 The Cause of Death Register 
The cause of Death Register includes information on historical deaths since 1961. Historical 
data is available from 1952-1960. From year 2011 the register includes data on all deceased 
individuals who at the time of death were registered in Sweden. From 2012 it includes all 
deaths occurring in Sweden. Diagnoses are, in contrast to the NPR, coded using the 
international ICD version and not the Swedish version (97).  
3.2.1.4 The Swedish Cancer register  
Registration of all newly detected cancers is mandatory by all care providers in Sweden. The 
Swedish Cancer register has coverage of 100% of all cancers that have been detected in 
Sweden since 1958. Information on diagnosis date, cancer type and site is available in the 
register as well as reporting hospital and department (98). 
3.2.1.5 The Swedish Tuberculosis Register  
The Swedish Tuberculosis Register includes information on all culture-confirmed cases of 
tuberculosis in Sweden since 1969, based on the mandatory reporting from treating doctor 
and tuberculosis laboratories. 
3.2.2 The Swedish Rheumatology Quality Register (SRQ)  
SRQ is a quality-of-care register used in everyday clinical practice to store information on 
patient diagnosis, treatment, and disease activity variables longitudinally since 1995 and is 
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governed by the Swedish Rheumatology Society. The SRQ includes IIM specific variables 
including the International Myositis Assessment and Clinical Studies (IMACS) core set 
measures since 2003 (99). The coverage of individuals with early RA was 78% in 2012 
depending on the register based definition 83.7% of prevalent cases were included in SRQ in 
2016 while the coverage of IIM is not known (100,101). In SRQ, IIM patients are assigned 
specific sub-diagnoses: PM, DM, IBM, JDM and unspecified myositis. 
3.2.3 Demographics databases  
3.2.3.1 The Total Population Register  
Statistics Sweden has been responsible for the Total Population Register since 1969. The TPR 
is a subset of the population register at the Swedish Tax agency and includes data on 
residency, migration, civil status and more and was used to sample matched general 
population controls for identified IIM individuals (102).  
3.2.3.2 Longitudinal integration database for health insurance and labour market studies 
(LISA) 
LISA includes all individuals older than 16 (15 years since 2010) years and registered in Sweden 
as of December 31 of each year and holds longitudinal information on educational level, 
health insurance usage and labour market availability (103).  
3.3 METHODOLOGICAL CONSIDERATIONS 
This section will give a brief overview of epidemiological study designs and other 
methodological considerations in this thesis. 
3.3.1 Sources of bias 
Here I present the three sources of bias, or systematic error, that can be present in 
observation studies and which can lead to incorrect estimates. These biases commonly have 
other names but structurally they can be classified into three categories.  
I will describe the structure of these biases by using directed acyclic graphs (DAGs). DAGs 
consist of different nodes, representing different variables, connected by arrows, or edges. 
Arrows indicate a causal relationship between two variables and the variable at the start of 
the arrow must both proceed and affect the variable at the end of the arrow (Figure 2).  
 
Figure 2. Simple directed acyclic graph where A causes Y. 
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For there to be an effect of A on Y there must be a direct path going from A to Y (through 
any other possible mediators). There are only two types of unblocked paths, direct paths 
and backdoor paths through a shared ancestor in DAGs. A marginal (crude) association 
requires an unblocked path between the two variables but this does however only imply 
association and not a causal effect. Direct paths imply a casual effect while a backdoor paths 
only imply an association between the variables (104). 
3.3.1.1 Measurement bias 
Data are seldom perfect and one must therefore take into consideration the risk of having 
incorrect information. The register sources that we are using in these studies are great and 
even though they present a detailed reflection of reality this reflection will always be 
somewhat distorted. Data can be coded incorrectly or the algorithm used to define a disease 
state might be incorrect.  
This is called misclassification, meaning that the measured value is not equal to the true value 
and can lead to bias. Misclassification can be differential, meaning that measurement of 
exposure is affected by the outcome status (Figure 3), or the other way around. Non-
differential misclassification normally affect the estimate towards the null while differential 
measurement error can either increase or decrease an association. 
 
Figure 3. One example of differential misclassification where A = exposure, A* = measured value of A, UA = measurement 
error for A, Y = outcome, Y* = measured value of Y and UY = measurement error of Y. 
In this thesis we estimate the positive predictive value (PPV) and specificity to describe the 
risk of misclassification of our register based definition of IIM sub diagnoses. PPV is the 
proportion of your positive cases (true positive + false positive) that are actually positive (true 
positive) from your test while sensitivity is the proportion of positives (true positive) that are 
correctly identified as such. 
𝑃𝑃𝑉 =
𝑇𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒
 
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =  
𝑇𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝑓𝑎𝑙𝑠𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒
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3.3.1.2 Confounding 
Confounding can arise in the presence of common causes of exposure and outcome. The 
presence of confounding in a study creates or affects the association between exposure and 
outcome. The idea of confounding can be described in a DAG. In Figure 4 it is clear that a 
change in C would affect both A and Y and therefore create a non-causal association 
between A and Y (105). 
 
Figure 4. A directed acyclic graph describing confounding. C = confounding variable, A = Exposure, Y = Outcome 
3.3.1.3 Selection bias 
Selection bias historically has had many different definitions and one common definition, 
which we will use in this thesis, is conditioning on a common effect of the exposure and the 
outcome (Figure 5). Common names of different types of selection bias include incorrect 
selection of controls in case-control studies, informative censoring, volunteer bias (baseline 
selection) and healthy worker effect which all can be described the same way structurally 
(106). 
 
Figure 5. Directed acyclic graph of selection bias. The box around C means we are conditioning on this variable. 
 
If confounding is very intuitive after just thinking about it for a bit, selection bias is the 
opposite and is often difficult to discover. Selection bias may arise when individuals are 
selected into the analyses based on certain characteristics. However, one should keep in mind 
 20 
that selection is not necessarily the same as selection bias. In cohort studies, it is common 
to select a specific group of individuals to optimize analyses (confounding distribution, 
number of outcome events etc.). This does not necessarily introduce selection bias but 
might affect the generalisability (external validity) of your findings. Rather, the selection 
must be affected by both exposure and outcome for selection bias to occur and result in 
biased estimates (105,107).  
3.3.2 Epidemiological study designs 
3.3.2.1 Cohort studies 
Cohort studies are the most intuitive study designs for investigating exposure-outcome 
relationships. Individuals are categorized on exposure status, followed up until the event of 
interest (outcome) occurs or until censoring and the frequency of the outcome is compared 
between the exposure groups. In contrast to randomized experiments, when exposure status 
is assigned through randomization, exposure varies for reasons outside of the investigators 
control in observational cohort studies. While randomization is the best weapon against 
confounding RCTs often have short follow-up and often include a highly selected population. 
Observational cohorts on the other hand have long follow-up and high generalizability by 
sampling a large representative part of the source population. Still, because randomization is 
not performed confounding must be handled in other ways, often through conditioning on 
the confounding variables.  
3.3.2.2 Case-Control studies 
To study a rare disease in a cohort study one would need a large number of person years, 
which can be retrieved either through a large number of participants enrolled at baseline or 
a very long follow-up period. This is often not efficient and instead the case-control design is 
often preferred. In case-control studies, instead of collecting data on all exposed and 
unexposed one can instead select all individuals with the outcome of interest (cases) and then 
sample controls from the same source population as from which the cases arose. The whole 
study population is then classified based on whether they previously have been exposed and 
the controls are used to describe the distribution of exposures and confounders in the source 
population. If the prevalence of the disease is rare and controls are sampled from a dynamic 
population at the time each case arise, the odds ratio, used to estimate association between 
exposure and outcome in case-control studies, approximates the incidence rate ratio 
(108,109).  
3.3.2.3 Matching 
When controls in a case-control study or comparators in a cohort study are not sampled at 
random but rather are selected based on specific attributes it is called matching. In the studies 
included in this thesis individuals are sampled from the general population matched on age, 
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sex and place of residence at the time of a case´s first IIM diagnosis. This is called density 
sampling or risk set sampling (109,110). Matching fulfils different purposes in cohort studies 
and in case-control studies. Matching on certain characteristics in a cohort study that may 
affect both the exposure and the outcome is one way of dealing with confounding because 
the distribution of matching variables are the same for the exposed and unexposed group 
(111). In case-control studies the matching first affects the way the odds ratio is interpreted 
and by using density sampling, the odds ratio used to estimate the association between 
exposure and outcome in case-control studies estimates the rate ratio directly but when 
sampling is carried out from a dynamic population, the analyses have to take matching on 
time in to account (conditioning on the matching strata) (110). Thus, matching in a case-
control study does not, in contrast to cohort studies, remove the potential confounding effect 
of the matching variables. Instead, matching is used for a more efficient statistical analysis, 
ensuring an even distribution of cases and controls in the matching strata (108).  
3.4 STUDY POPULATIONS 
Individuals with IIM were identified using the same methodology for all four studies, namely 
via the NPR using ICD10 codes (Table 1) and via SRQ. The linkage of multiple registers, 
described in the section Data sources enabled us the get longitudinal information, both 
before and after IIM diagnosis, on medical conditions requiring healthcare, drug 
dispensations, cancer, deaths as well as census data, including educational level and place of 
residence, from Statistics Sweden (Figure 6). The validity of ICD codes used to identify IIM 
have previous been investigated in Sweden partly including the same study population as in 
this thesis.  The PPV was then estimated to be 88% (64). 
 
Figure 6. Description of sources used to 1. Identify IIM from the National Patient Register (NPR) and the Swedish Rheumatology 
Quality register (SRQ), 2. Sample age, sex and place of residence matched general population cohort and 3. Linking of 
additional data s 
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Table 1. ICD10 codes used to identify idiopathic inflammatory myopathies from cases from the 
national patient register. 
ICD10 code Text Diagnosis 
G724 Inflammatory myopathy, not elsewhere classified Inclusion body myositis 
M330 Juvenile dermatomyositis Juvenile DM 
M331 Other dermatomyositis Dermatomyositis 
M332 Polymyositis Polymyositis 
M339 Dermatopolymyositis, unspecified Dermatomyositis 
M608 Other myositis Unspecified 
M609 Myositis, unspecified Unspecified 
ICD10 = International Classification of Disease version 10 
3.4.1.1 IIM patients 
In study 1 a wider range of ICD codes were used for identification than for studies 2-4 because 
the registers were only used to identify individuals suspected of having IIM. The initial 
identification was then followed by medical chart review which enabled verification of 
diagnosis. Medical charts were reviewed for individuals with a visit indicating IIM and biologic 
treatment. Biologic agents were identified from the PDR (Table 2) and SRQ and subjects were 
included after verifying diagnosis and treatment indication. A physician given IIM diagnosis 
was sufficient for inclusion but diagnosis was also verified using diagnostic criteria (4–6,12). 
Also, only had NPR data up until December 31 2011 as it was based on a different and older 
linkage of the registers only including suspected IIM individuals. Individuals were identified 
between 2000 and 2011. 
Table 2. List of drugs used to identify DMARDs, corticosteroids and biologic agents 
from the prescribed drug register. 
Group ATC code Drug 
  L04AA13 leflunomide 
  L04AA06 mycophenolate mofetil 
  L04AX01 azathioprine 
DMARD L04AD01 cyclosporine 
  L04AD02 tacrolimus 
  L04AX03 
methotrexate 
  L01BA01 
  L01AA01 cyclophosphamide 
Corticosteroids H02AB06 prednisolone 
  L04AB02 infliximab 
  L04AB01 etanercept 
  L01XC02 rituximab 
Biologics L04AC03 anakinra 
  L04AA24 abatacept 
  L01XC04 alemtuzumab 
  L04AB04 adalimumab 
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The aims of study 2 were both to develop a register based algorithm for identification of IIM 
which were to be used in the following studies. Also, we wanted to estimate the incidence 
rate and prevalence of IIM in Sweden. Possible IIM individuals were identified as for study 1 
but study 2 only included visits at specialist clinics (rheumatology, neurology, internal 
medicine, dermatology and paediatric clinics) and ICD10 codes M60.8-9 were excluded in the 
main analyses due to primarily being used in diagnostic work up of IIM patients. Also, as both 
outpatient visits and hospitalization data were available 2001 through 2012, cases were 
identified between 2002 and 2011 to allow for a 12 month wash-out period prior study start 
to exclude prevalent cases, and 12 months following the first visit to allow for sufficient time 
for a follow-up visit.  
Three incidence and three prevalence case definitions were tested to describe robustness of 
estimates. 
Incidence case definitions: 
The index date was defined as the first ever IIM visit between 2007 and 2011 identified from 
the NPR or SRQ. The (1) liberal case definition was defined as having one or more visits while 
the (2) base case definition required one more visit 1-12 months following the index visit to 
exclude individuals under evaluation and possible miscodings if not registered in SRQ. The (3) 
strict case definition additionally required one or more dispensing of prednisolone or 
DMARDs within 12 months.  
Prevalence case definitions: 
The prevalence (2) base case definition required ≥2 specialist visits indicating IIM while the 
(1) liberal only required ≥1 visits while the (3) strict also required dispensation of prednisolone 
or DMARDs. 
The base case definition from study 2 was then used to define adult (≥18 years) IIM from the 
registers in studies 3-4.  
3.4.1.2 Comparators 
Studies 1-2, were pure descriptive studies only including individuals with IIM and therefore 
no comparison group was necessary. For studies 3-4 however, we wanted to investigate 
causality and prognosis so a control cohort sampled from the TPR was matched on age, sex 
and place or residence 10:1 to each case at time of first IIM visits and were used as controls 
in study 3 and comparators in study 4.  
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3.5 STUDY 1 – BIOLOGICS IN IIM 
Data on treatment, demographics, disease duration and disease activity variables were 
collected from medical charts and SRQ and described at start of first biologic therapy. Reason 
for stopping treatment was assessed within two years from starting biologic treatment.  
3.6 STUDY 2 – OCCURRENCE OF IIM 
Overall incidence was estimated between 2007 and 2011 and prevalence was estimated on 1 
January 2012 and stratified by age, sex, and clinical sub-diagnosis. In addition, age and sex 
standardized incidence rates were calculated for education level and place of residence.  
In addition, a number of alternative case definitions were tested in sensitivity analyses 
including varying the time allowed between first and second visit and excluding cases that 
had dispensed immunosuppressive medication within 6 and 12 months prior first IIM visit. 
We also estimated the specificity and PPV for included ICD10 codes ability to define clinical 
IIM sub-diagnosis with SRQ given diagnosis as the gold standard. 
3.7 STUDY 3 – RISK FACTORS FOR IIM 
In study 3, we wanted to investigate risk factors for IIM and therefore a case-control study 
was conducted with IIM as the outcome and respiratory diseases and infections as the 
exposure. Adult (≥18 years) newly diagnosed individuals with IIM were identified between 
2002 and 2011 using the base case incident definition from study 2 and the first registered 
visit was used as the index date. Visits indicating exposure were identified from the NPR using 
ICD codes. Infections included all infections while respiratory diseases excluded respiratory 
infections.  Infections were categorized based on location, including gastrointestinal, 
respiratory and skin while respiratory diseases were categorized into upper and lower 
respiratory infections. In addition to the NPR, tuberculosis was identified from the 
tuberculosis register. To decrease the risk of detection bias and reversed causality (outcome 
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causing the exposure) we introduced a latency period of 12 months between exposure and 
outcome.  
 
Figure 7. Previous infections and respiratory diseases are identified from the National Patient Register (NPR) for IIM patients 
and age, sex and place of residence matched general population controls. 
Measurement bias and residual confounding were of major concern when conducting the 
study. Individuals with IIM could potentially have poorer health due to an impaired immune 
system long before the development of IIM. This impaired immune system, which later causes 
IIM, could increase the risk of both infections and respiratory diseases or the detection 
thereof due to more frequent contact with healthcare. We therefore assessed the number of 
healthcare visits before exposure or before the outcome for unexposed individuals and used 
it as a proxy for general health and adjusted for it in the analyses. 
 
Figure 8. Directed acyclic graph describing how an impaired immune system (X) causes increased health care consumption 
(L) and measurement or risk of exposure (A) directly as well as development of later idiopathic inflammatory myopathies (Y). 
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We also conducted multiple sensitivity analyses to investigate the robustness of the 
estimates. The definition of exposures, latency period and sources used to identify exposures 
was changed and individuals with IIM associated conditions (connective tissue disorder, lung 
phenotype and cancer) were excluded in various analyses. 
3.8 STUDY 4 – RISK OF STROKE IN IIM 
In study 4 we conducted a cohort study with IIM as the exposure and ischemic and 
haemorrhagic stroke as the outcome (Figure 9). The same algorithm was used, as described 
in study 2 (but excluding SRQ as a source), to identify individuals with newly diagnosed IIM. 
The second IIM visit was used as index date and comparators were given the same index date. 
 
Figure 9. Patients with idiopathic inflammatory myopathies and age, sex and place of residence matched general population 
comparators were followed prospectively and hospitalizations and outpatient visits indicating haemorrhagic and ischemic 
stroke were identified from the national patient register (NPR). 
Ischemic and haemorrhagic strokes were identified from the NPR using ICD10 codes (Table 3) 
as well as from the cause of death register. Individuals with prior stroke or stroke related 
events were excluded from the study. As ischemic and haemorrhagic stroke is caused by 
different aetiology they were analysed separately. Follow-up was started at index date and 
ended at first stroke event under evaluation, death, migration or end of study (December 31 
2012). Prevalent stroke risk factors at baseline were also identified at baseline because they 
could be potential confounding factors, possibly increasing the risk of IIM as well as stroke 
and were adjusted for in sensitivity analysis. 
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Table 3. International classification of diseases (ICD)  
codes used to identify idiopathic inflammatory myopathies, stroke, stroke related events and 
stroke risk factors. 
  ICD9 ICD10 
Stroke risk factors     
Diabetes 250 E10, E11 
Hypertension 
401, 402, 403, 404, 
405 
I10, I11, I12, I13, I15 
Atrial fibrillation 427D I48 
Congestive heart disease 425, 428 I42, I50 
Stroke      
Ischaemic stroke 433 -434 I63 
Haemorrhagic stroke 431 I61 
Unspecified Stroke 436 I64 
Stroke related events     
Subarachnoid haemorrhage (SAH) 430 I60 
Sequele 438 
I69, Z86.6A-B,  
Z86.7C 
Transient ischemic attack (TIA) 435 G45 
 
3.9 STATISTICAL ANALYSES 
3.9.1 Logistic regression 
Exposure-outcome relationships are commonly analysed using logistic regression models in 
case-control studies and were used in study 3 to estimate the association between 
infections/respiratory diseases and IIM.  
Logistic regression is a generalized linear model used when trying to make inference on binary 
outcomes when the risk in the source population is not known (111). The relationship 
between predictor variables and the log-odds (logit) transformation of the probability of the 
outcome (O) given the exposure (X) is linear in the logistic regression model and predictors 
are estimates using the maximum likelihood function. 
𝑙𝑜𝑔𝑖𝑡(𝑃(𝑂|𝑋) = log (𝑜𝑑𝑑𝑠(𝑂|𝑋)) =  𝛽0 + 𝛽1𝑋 
The likelihood is the probability of obtaining the data that was observed for different 
predictors and maximum likelihood estimates of the regression coefficients are found by 
varying the combination of values that maximize the likelihood for the given set of data. In 
conditional logistic regression analysis is stratified and is often used in observational studies 
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when cases and controls are matched because it is more efficient and unconditional analyses 
can lead to biased estimates (112). 
3.9.2 Cox regression 
Time to event (or survival) analysis is most commonly done by using Cox proportional hazards 
models (113) (Cox regression) because in logistic regression, time cannot be taken into 
consideration. Cox regression was used in study 4 where time from IIM diagnosis to first 
incident haemorrhagic or ischemic stroke was modelled.  
3.9.2.1 General concepts 
There are two key concepts in survival analysis: (1) the hazard function (h(t)) and the (2) the 
survival function (S(t)) 
1. The hazard function 
The hazard (or hazard rate) at time t, is the incidence rate in a time interval around t that 
approaches zero and is sometimes called the instantaneous rate. The hazard ratio (HR), is the 
hazard in the exposed group divided by the hazard in the unexposed group and can for all 
practical reason be interpreted as an incidence rate ratio (IRR). 
The Cox model relates the hazards (h) to a set of covariates(X) and associated regression 
coefficients (β) at time t and is used to estimate the relative effect of covariates on the hazard 
function. 
ℎ(𝑡) = ℎ0(t) exp(βX) 
ho = the baseline hazard, the hazard when X = 0. 
The failure function, F(t)  =  Pr(T ≤  t), describes the incidence of the outcome over the 
duration of the study, where T = time to event of interest.  
2. The survival function 
The survival function is the complement of the failure function:  
S(t) = 1 –  F(t) = Pr(T >  t) 
and describes the probability of having survived until time t and is often estimated using the 
Kaplan-Meier estimator. The relationship between the survival function and regression 
coefficients (β) from the Cox model can be described as: 𝑆(𝑡) = 𝑆0(𝑡)
exp(βX), where 𝑆0 
denotes the baseline survival function (the survival function for an individual where all 
covariates equal zero. So, the effect of a specific variable on the relative effect of the hazard 
(the HR) equals the relative effect of that variable on the logarithm of the survival function 
(114,115) . 
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3.9.2.2 Competing risk analyses 
Censoring is a distinctive feature of survival analysis data. Examples of censoring events are 
death or emigration and lead to loss to follow-up for that individual and the possible timing 
of the outcome is not known. These individuals are commonly excluded from the analyses at 
censoring and stop contributing person-time. The main assumption made in traditional 
statistical analyses methods of survival data is that at a given point, individuals that remain in 
the risk set should have the same future risk of the outcome as individuals who are censored. 
When the censoring is informative, this is not the case because the censoring is associated 
with the exposure which leads to selection bias.  
A competing event is an event that either hinders or affects the probability of the main event. 
The cumulative incidence function (CIF) is a proper summary statistics for competing risk data 
if the question is prognostic rather than casual. The CIF, in contrast to 1 - S(t), can be used to 
estimate the incidence of the occurrence of an event while taking competing risks into 
account. The CIF for the cause k is defined as  𝐶𝐼𝐹𝑘(𝑡) = Pr (𝑡 ≤ 𝑇, 𝑒𝑣𝑒𝑛𝑡 = 𝑘) and is linked 




A common question in medical research is often therefore to assess a covariate effect on the 
CIF. In the absence of competing events, 1 – the Kaplan-Meier estimator gives a correct 
estimation of the CIF. However, in the presence of competing risks, estimates are biased 
upwards even if the competing event and the main event are independent (114,116,117).  
One way to analyse competing risk data is to use the sub-distribution hazard function, 
introduced by Fine and Gray (118). Instead of estimating the hazard in those who have not 
yet experienced the main event or any competing events, the sub-distribution hazard 
function estimates the hazard in those who have not yet experienced the main event. Another 
way to explain it is that individuals who experience a competing risk are not censored but are 
rather kept in the risk set and given a weight depending on the risk of the main event (Figure 
10). The advantage of the sub-distribution hazard is that one can make inference on a 
variables effect on the cumulative incidence function even in the presence of competing risks. 
 
Figure 10. A cohort of 6 individuals followed over time with stroke as the main outcome. In competing risk analysis, 
individuals are kept in the risk set after censoring events (death) and continue to contribute person-time in contrast to cause-
specific survival analysis. 
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3.10 ETHICAL CONSIDERATIONS 
Because we handle sensitive personal information concerning individual´s health, data are 
stored and managed accordingly. Data are kept at secure servers according to KI guidelines 
and only processed in relation to our specific research questions. A minimum of new data was 
collected from medical records of a subset of identified patients to minimize the breach of 
the individual´s personal integrity. In general, the risks of using register based data are 
considered small because data stored in available databases are normally sufficient. 
Furthermore, data is normally pseudo-anonymized (PIN is replaced by key) making 
identification of research subjects more difficult. IIM is a rare disease making it difficult to 
perform large studies and epidemiological studies are lacking in the field. Much is still 
unknown about the disease but with the use of Swedish registers it is possible to further the 
understanding of this difficult disease. 
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4 RESULTS 
Here, the main results for the included studies are presented. 
4.1 STUDY 1 
We identified 95 patients with IIM who were treated with biologics off label between 2000 
and 2011. Diagnosis and treatment were confirmed via review of clinical charts. Median 
disease duration was 5.5 years before start of first biologic treatment and all had previously 
failed multiple previous treatments for their IIM. Rituximab was the most commonly used 
drug even though the first treated patient was identified in 2003 (Figure 11). Median 
treatment length varied between 5 to 12.5 months for the different agents but because of 
different regimens and dose intervals it was difficult conclude if they were really different. 
More than one biologic was prescribed to 28% of patients. 
 
Figure 11. Total number of patients with idiopathic inflammatory myopathies treated with different biologic agents between 
2000 and 2011. TNF-inhibitors = etanercept, adalimumab, infliximab. 
4.2 STUDY 2 
Between 2007 and 2011, 522 individuals were defined as having incident IIM according to the 
basecase definition corresponding to an average incidence rate of 11 (95%CI 10-12) per 
1 000 000 person-years. Rates remained similar when applying more strict and liberal case 
definitions (Figure 12). The incidence rates generally increased with age but with a peak 
between 50-79 years and incidence was highest for the 70-79 year age group with higher 
rates in women for most age groups. Even though large variations were found between 
Sweden´s 21 counties, no north to south gradient of incidence rates was observed for overall 




Figure 12. (A) Mean annual incidence rates per 1 000 000 person years and (B) prevalence per 100 000 of idiopathic 




Figure 13. Heat map of incidence rates by Sweden’s 21 counties Difference (%) in age and sex standardized incidence rates 
compared with overall incidence rate for idiopathic inflammatory myositis (left) and DM (right) for Sweden’s 21 counties.  
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Prevalence was estimated to 14 (95%CI 13-14) per 100 000 on 1 January 2012 when using the 
base case definition. Estimates were highest for women in all age groups and the overall 
prevalence were 17 and 11 per 100 000 for women and men respectively.  
We also found that sensitivity and PPV for most included ICD codes were high when using 
SRQ given diagnosis as the gold standard. However, it was difficult to separate IBM from PM 
because of low specificity for ICD code used to define IBM and low PPV for ICD code used to 
specify IBM. 
4.3 STUDY 3 
We identified 957 IIM cases and 9576 controls from the NPR and SRQ that fulfilled the 
inclusion criteria between 2002 and 2011. Previous infections were identified in 125 (13%) of 
IIM cases and 877 (9%) of controls. Previous infections were associated with increased future 
risk to develop IIM, OR 1.5 (95%CI 1.2 - 1.9). The association was true for both infections of 
the gastrointestinal and respiratory tract but not for infections of the skin (Figure 14). 
We also observed a dose response relationship for both exposures in that the ORs increased 
with number of previous visits (Figure 15). 
 
 




Figure 15. Number of visits indicating exposure and corresponding odds ratio (OR) for infections and respiratory tract 
diseases. 
We conducted multiple sensitivity analyses to investigate the robustness and to find 
alternative explanations to our findings. We varied the latency period between exposure and 
outcome, changed the exposure definition and data sources used to identify exposures, 
excluded other IIM associated conditions which potentially could be driving the associations 
and finally we adjusted for previous health care consumption as a proxy for general health. 
None, did however change the overall interpretation of our results. 
4.4 STUDY 4 
Between 2002 and 2011 we identified a total of 716 new cases of IIM from the NPR that 
fulfilled our case definition. After exclusion for prior stroke or stroke related events 663 and 
6673 were included in the IIM and general comparator cohorts. 
We observed a younger age at first incident stroke and shorter median follow-up time for IIM 
patients indicating that they either experience their stroke at an earlier age than their 
comparators. We also observe a higher degree of censoring due to death in the IIM (24%) 
cohort compared to the comparator cohort (8%).  
Association between IIM and stroke 
For haemorrhagic stroke, the age and sex adjusted HR was 2.4 (95%CI 0.8-7.1) and the rate 
difference 0.5 (95%CI -0.6-1.6). Because the number of events was low, 4 in IIM and 22 in 
comparators, only overall estimates were calculated for HS. 
For ischemic stroke, 22 events were identified in IIM and 174 in the comparators. The overall 
HR was 1.7 (95%CI 1.1-2.7) and the rate difference 2.6 (95%CI 0.0-5.3). 
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The absolute rates of IS were the highest in the oldest age group (≥68) and in men relative 
risk of IS was highest in the youngest age group (<56 years) while the rate difference was 
highest in the youngest and oldest age group (Figure 16). 
 
Figure 16. Absolute risk, risk difference and hazard ratios for ischemic stroke in idiopathic inflammatory myopathies (IIM) 
patients compared to general population comparators. 
Competing risk of death 
When taking the competing risk of death into account using Fine and Gray´s competing risk 
models, the sub-distribution HR (sd-HR) was lower, 1.3 (95%CI 0.8-2.0), compared to the HR 
from the cause specific model. The cumulative incidence was increased in IIM compared to 
comparators directly following diagnosis but was similar at 10 years the risk of death is 
significantly higher for IIM than in comparators (Figure 17). 
Stroke risk in relation to time since IIM diagnosis 
The relative risk of ischemic stroke was the highest the year following diagnosis (Figure 18). 
The increased risk persisted for up to five years but was then similar between IIM and 











Figure 18. The risk of ischemic stroke in relation to diagnosis of idiopathic inflammatory myopathies (IIM). 
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5 DISCUSSION 
5.1 SUMMARY 
By using Swedish registers we have, first, described how biologics have been used in an off-
label real world setting. Second, estimated the incidence rates and prevalence of IIM in 
Sweden with high level of detail (stratified by age, sex, population density and educational 
level) while also addressing the possible limitations of using register based algorithms for case 
identification. Third, we have shown that both infections and, more so, respiratory diseases 
increase the future risk of developing IIM. Last, we have demonstrated an increased risk of 
stroke in patients with IIM and that the risk was elevated directly following disease diagnosis. 
We have been able to demonstrate the advantages of using population based registers for 
investigating both descriptive, causal and predictive epidemiological questions regarding a 
rare disease and have been able to contribute with new knowledge as well as establishing 
prior believes. Strong observational population based study design with long term follow-up 
and the possibility to look both forwards and backwards in time in relation to IIM diagnosis 
enables investigation of many outcomes and risk factors. This method includes real world 
patients and data with good coverage, enabling identification of all IIM patients in Sweden. 
Because IIM is such a rare disease it is challenging to study because of problems recruiting 
study subjects, thus using these comprehensive register sources should be of great 
importance moving IIM research forward. 
5.2 PREVIOUS RESEARCH AND IMPLICATIONS 
5.2.1 Study 1 
Since the initiation of this study, a few clinical trials have investigated the effectiveness of 
biologics in IIM. Rituximab seem to be effective in a subset of patients, especially patients 
with anti-Jo1-antibodies (25,32,33,119). Abatacept treatment was recently shown to 
decrease disease activity in almost half of the included patients in one study (119). A similar 
effect was observed in 15 patients treated with anakinra (25). 
Our results from study 1 indicate that biologics is commonly used to treat IIM and that the 
use has increased over time and that a shift in type of drug has occurred. This real world 
description of use is important as it demonstrates that even though so little effectiveness data 
is available, the use is still common. This overall increased use of biologic therapies during the 
last years of the study could be explained by an increased number of agents being available 
or the added availability of the PDR from 2005 as well as the increased number of published 
reports in IIM but it may also suggest an unmet need for new therapies in IIM. Therefore, 
greater efforts should be made upon trying to collect effectiveness data on all treated patients 
in a structured way, preferably in national or international registers such as SRQ and 
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Euromyositis, enabling studies which determine which treatments work for different patient 
groups.  
While conducting the first study I scrutinized the medical charts of many patients with IIM. 
This process enabled me to get to know this disease better and made me understand what a 
heterogeneous group of patients it includes. I was also able to understand how difficult the 
diagnosis of IIM really is and how difficult it is to verify diagnosis retrospectively using 
diagnostic criteria.  
5.2.2 Study 2 
With this study, using a population-based design including Sweden´s almost 10 million 
citizens, it is one of the largest studies to date on juvenile and adult IIM. The occurrence of 
IIM has been estimated previously but with large variations making the actual estimates 
uncertain. In Sweden incidence has previously been estimated to 2.2 and 7.6 per 1 000 000 
person-years for IBM and PM-DM respectively(37,38) while internationally, incidence has 
been estimated as low as 1.2 and as high as 66 per 1,000,000 person-years (40,44) while 
prevalence has varied between 0.49 and 32 per 100,000 (47,120).  
We were able to produce stable estimates in line with previous regional diagnosis verified 
studies on IIM prevalence from Norway (50,51) and a recently published meta-analysis (121). 
The same meta-analysis estimated incidence to be somewhat lower, 8 per 1,000,000 person-
years, compared to ours. 
In contrast to what is commonly reported, we did not find incidence by age to be bimodal but 
rather, a steady increase in incidence was observed up to the 80+ years for both men and 
women and a clear peak in the 50-59 age groups, which is higher than previously reported in 
Taiwan (46) but similar to studies from the USA and Australia (40,47,48).  
Previous studies have demonstrated both a difference in incidence comparing rural to urban 
(49) as well as a north to south gradient (56,57,121) while we found no evidence of this. This 
could be explained by Sweden being one of Europe´s most northern countries.  
To our knowledge, incidence rates of IIM has not previously been estimated based on 
educational level. In contrast to what has been found in RA (122,123) we found no difference 
between different levels of education. 
Results from study 2 indicate that neither incidence nor prevalence is as high as recently 
reported in register based studies in US and Canada. Neither did we find any time trend 
indicating IIM becoming more common like what some recent studies have implicated. This 
study also demonstrated the importance of clear and transparent case definitions when 
identifying disease and demonstrates the effects they can have on estimates. 
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5.2.3 Study 3 
Our results indicate that both respiratory diseases and infections increase the risk of 
developing IIM. Previous studies have suggested similar connections for infections but  
evidence has been limited due to studies only including prevalent cases, using a cross 
sectional design, or case reports making it difficult to infer anything about the temporality of 
the association (70,76,124–126). Concerning respiratory diseases it has long been known that 
many individuals with IIM suffer from respiratory diseases to a high degree already at disease 
diagnosis (60) but no causal relationship has been established. A recent case control study 
including hospitalised IIM found increased levels of exposure of sarcoidosis, pneumonia and 
tuberculosis compared to controls (64). This study does however rely on questionnaires, 
which could introduce measurement bias, and only hospitalised individuals were included, 
which could cause problems both with selection bias and with generalizability. Furthermore, 
our results are based on a wider definition of respiratory diseases. 
Only including exposures occurring more than one year before IIM diagnosis enabled us to 
investigate factors having larger impact on disease development than triggering factors 
occurring in close proximity to disease. Furthermore, this design decreases the risk of 
detection bias and reversed causality. Also, using national registers with long follow-up it is 
possible to identify exposures occurring in an early stage in disease development. We believe 
this time window is of greater importance for causes of disease as the mechanisms leading to 
IIM may occur many years before disease onset as immunomodulation later leading to 
disease may be triggered by exposures many years before disease onset.  
In this study, much focus was put into sensitivity analyses, especially adjusting for previous 
health care consumption. As cases might have poorer health, leading to more contact with 
health care and later IIM. We therefore adjusted for previous health care consumption in the 
statistical analysis to remove the effect of this possible confounder. The associations were 
slightly decreased but our conclusions were not affected. 
Our results suggest that inflammatory events that may follow infections and respiratory 
disease may play a role in disease pathogenesis and that the location of exposure may play a 
role and further studies should be carried out finding the biologic mechanisms related to this 
relationship. Previously suggested mechanisms of infections causing autoimmune diseases 
included molecular mimicry, where a foreign antigen shares structural similarities with self-
antigens (77) and change in gut microbiota, affecting immunoregulatory mechanisms (127). 
Also, just like infections, many respiratory diseases like asthma and chronic obstructive 
pulmonary disease (COPD) lead to an increased inflammatory load and an activation of the 
immune system, which could cause autoimmunity through priming of self-reactive 
lymphocytes and autoantibody production (78,128). 
 40 
5.2.4 Study 4 
The risk of both ischemic and haemorrhagic stroke seems to be elevated in individuals with 
IIM compared to the general population and the risks are especially high in older individuals 
and in men. Our estimate of IS is similar to what was recently reported in a meta-analysis 
(129) where the pooled risk ratio was estimated to 1.6 but somewhat lower compared to a 
recent Canadian study, HR 2.5 (130). Most previous studies have failed to separate HS from 
IS which might be problematic as they have different aetiologies and should be analysed 
separately (91,92,130). 
Because it has previously been shown that IIM has an increased risk of death (80) and death 
is a competing event for stroke as it hinders the event of interest (stroke), the cause specific 
hazard is not describing the risk of stroke from a prognostic perspective as it estimates the 
effect on the rate of occurrence of the outcome in subjects who are currently event free (both 
main event and competing events). Because censoring due to death is informative, the 
individuals remaining in the risk set in cause specific Cox models are not representative of the 
censored individuals. We therefore used sub-distribution hazard models to better describe 
the risk in the context of prognosis. The sd-HR was decreased by 40% compared to the HR 
from the cause specific models and the cumulative incidence of ischemic stroke was elevated 
early in disease but then reached levels in line with the general population after 10 years. 
We were not able to investigate the biological mechanism and of the increased risk of stroke 
in these IIM patients. Inflammatory markers like C-reactive protein have been associated with 
an increased risk of stroke but as these markers seldom are elevated in IIM, other mechanisms 
must be involved. Further efforts should therefore be made into combining epidemiological 
methods with laboratory and clinical data to better describe exposures and outcome and to 
find possible causal and biologic pathways for suggested associations.  
Even if the risk of both IS and HS is increased in patients with IIM, it should be kept in mind 
that these are rare events and focus on prevention should therefore be made in the groups 
with the highest absolute risk, especially older individuals and men. 
5.3 STRENGTHS 
The data sources used to identify both individuals with IIM, outcomes, exposures, 
confounders, comorbidities and other important information were strengths of this thesis. 
Using population based registers with good coverage we were able to identify an unselected 
population, and we were able to describe a rare condition in a real world setting with high 
generalizability to other populations. The main strength is that we managed to identify all 
individuals followed for IIM in Sweden. The possibility to compare IIM to the general 
population and look both forward and backward in time enables addressing a wide range of 
research question in this rare disease. Also, this register linkage can later be reproduced to 
investigate time trends of specific research questions. Finally, all data in included registers is 
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prospectively collected minimizing the risk of recall and detection bias as well as non-
response. 
5.4 LIMITATIONS 
Register based case definition 
We did not review medical records of all identified patients to ascertain diagnosis. Instead we 
chose to use an algorithm which tries to mimic the patient´s flow through the healthcare 
system to identify patients. As shown in study 1, diagnosis ascertainment using diagnostic 
criteria retrospectively can prove difficult due criteria requiring several investigations, 
especially EMG and muscle biopsies, that might not always be necessary in a clinical context. 
Defining patients based on classification criteria using retrospective chart review would 
therefore have a high risk to exclude many true cases as not all patients with IIM present a 
typical biopsy finding or EMG and muscle biopsy may not even have been performed. The 
introduction of new classification criteria will surely help in this context  (131)  
There is always a limitation using register based case definition / identification of cases. 
Considering this limitation and the future studies planned we concluded that it was more 
important with a stricter case definition in contrast to a more liberal. This because the effect 
of including false positive cases would potentially have large effects on planned studies 3 and 
4 where IIM would be the outcome and exposure in respective study. Such misclassification 
of the outcome and exposure would in most cases move the estimates towards the null.  
Misclassification of exposure and outcome 
Like with IIM diagnosis, there is a risk of misclassifying other variables, such as exposures and 
outcomes. We have not ascertained the exposure and outcome status in study 3 and study 4 
but rather relied on the identification from the registers. As previously addressed, this has led 
to some misclassification as we cannot identify, for instance, the common cold and other 
exposures only requiring primary care or no care at all.  
Separating sub-diagnosis  
When investigating sensitivity and positive predictive value of included ICD10 we came to 
realize that it was difficult to separate PM from IBM because of overlapping use of ICD codes. 
Also, the estimates of incident IBM was less than half of what has previous been reported in 
Sweden (38) and when comparing to the proportion registered in SRQ, 15% had IBM 
compared to 7% when using ICD codes. This is because there is no specific ICD code for IBM 
and therefore the code for PM is commonly used in clinical practice. We were therefore 
unable to correctly separate these two sub-diagnosis and therefore, these clinical sub-
diagnoses were analysed together in study 3 and 4. A more recently identified subgroup, the 
immune mediated necrotizing myopathy, has no separate ICD code and does not yet have an 
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own code in SRQ so we assume that these patients are also included among the PM cases. 
This demonstrates the need for specific ICD codes for all sub-types of IIM. 
Missing variables 
Residual and unmeasured confounding is a major concern in all observational studies as it can 
cause associations that are not casual. For us, smoking status and other life-style factors were 
missing making it impossible for us to investigate their effects. Furthermore, we did not have 
detailed clinical and laboratory data available on study subjects, making it difficult to identify 
clinical subsets and to identify biologic mechanisms explaining observed associations. 
5.5 CONCLUSIONS 
By using population based registers and observation study designs it is possible to overcome 
many problems caused by IIM being a rare disease. Finding a sufficiently large study 
population can be cumbersome in such diseases and therefore this methodology is of a great 
resource for moving research on this serious disease forward and can help answer both 
descriptive, prognostic and causal questions. We found that: 
• Biologic agents are frequently being used to treat IIM off-label and an overall 
increased use over time was observed. Treated patients had all previously failed at 
least one DMARD and prednisolone. 
• Using our register-based case defintion we were able to produce robust estimates of 
the occurrence of IIM, describe how it varies over sub-groups and to investigate 
spatial trends. Incidence increased with age for both men and women while no 
difference were seen based on educational level and place of residence. 
• Both respiratory diseases and infections increase the future risk to develop IIM. 
Infections of the respiratory and gastrointestinal tract are associated with an 
increased future risk while infections of the skin are not indicating that site of 
increased inflammatory load might play a role in disease pathogenesis.  
• There is an increased risk of both ischemic and haemorrhagic stroke following an IIM 
diagnosis and the risk is the highest up to 5 years after disease debut. Stroke is 
however a rare event in these individuals and in the context of prognosis, the 
cumulative incidence is similar compared to the general population over 10 years. 
Efforts of prevention should be made in the groups with the highest absolute risk, 
newly diagnosed, the oldest age group and men. 
5.6 FUTURE RESEARCH 
I believe, that with this thesis, we have illustrated the power of these methods, but also some 
of its flaws. We might be able to draw conclusions based on large amounts of data but we are 
at the same time limited in making conclusions richer in detail. As previously discussed, efforts 
should be made on including all IIM patients in national or international registers like SRQ or 
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Euromyositis, where diagnosis and clinical subtype is ascertained. Also, all patients treated 
with biologics should be carefully monitored and effectiveness measures should be done 
routinely.  
Linking of other sources, such as biobank data, could help produce better and more detailed 
estimates enabling a further understanding of the pathophysiology of IIM. In the meantime, 
basic research should try to answer mechanisms involved in identified risk factors as well as 
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